Citadel Advisors
FDMT icon

Citadel Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Citadel Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Sell
29,300
-6,000
-17% -$52.2K ﹤0.01% 10686
2025
Q4 		$265K Buy
35,300
+12,100
+52% +$123K ﹤0.01% 10416
2025
Q3 		$202K Buy
23,200
+7,200
+45% +$43K ﹤0.01% 11248
2025
Q2 		$59.4K Sell
16,000
-9,800
-38% -$34.5K ﹤0.01% 11684
2025
Q1 		$83.3K Sell
25,800
-20,300
-44% -$95.6K ﹤0.01% 11713
2024
Q4 		$257K Buy
46,100
+8,400
+22% +$65.9K ﹤0.01% 9971
2024
Q3 		$408K Buy
37,700
+31,800
+539% +$528K ﹤0.01% 8693
2024
Q2 		$124K Sell
5,900
-67,400
-92% -$1.69M ﹤0.01% 10618
2024
Q1 		$2.34M Buy
73,300
+48,000
+190% +$1.22M ﹤0.01% 5220
2023
Q4 		$513K Buy
25,300
+20,500
+427% +$270K ﹤0.01% 8047
2023
Q3 		$61.1K Sell
4,800
-5,300
-52% -$88.6K ﹤0.01% 11509
2023
Q2 		$183K Buy
10,100
+3,200
+46% +$58.9K ﹤0.01% 10032
2023
Q1 		$119K Sell
6,900
-12,400
-64% -$241K ﹤0.01% 11014
2022
Q4 		$429K Sell
19,300
-70,100
-78% -$1.08M ﹤0.01% 8563
2022
Q3 		$719K Sell
89,400
-23,400
-21% -$212K ﹤0.01% 7698
2022
Q2 		$787K Buy
112,800
+35,500
+46% +$345K ﹤0.01% 7577
2022
Q1 		$1.17M Buy
+77,300
New +$1.21M ﹤0.01% 7352

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's FDMT Position: Q1 2026 in Review

Citadel Advisors increased its 4D Molecular Therapeutics (FDMT) stake by 1,228% in Q1 2026, buying an estimated $2.13M and bringing the position to 264,096 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5660.

Citadel Advisors first reported a position in FDMT in Q4 2020 and has held it in 20 quarters since. The position peaked at $3.37M in Q4 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Citadel Advisors held 264,096 shares of 4D Molecular Therapeutics worth $2.46M as of Q1 2026.
  • Citadel Advisors bought 244,207 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.13M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5660 holding.
  • Citadel Advisors first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Citadel Advisors's 4D Molecular Therapeutics position peaked at $3.37M in Q4 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.